Abnormal activation of YAP/TAZ is detected in many solid tumours, including breast cancer, cholangiocarcinoma, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer [23,24,25,26,31,32,33,34]. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.